Asbestos & Mesothelioma Studies

PARP Inhibitors Could Soon Help Mesothelioma Patients

There is a new treatment involving PARP inhibitors that could potentially benefit mesothelioma patients. PARP stands for Poly (ADP-ribose) polymerase. PARP is typically involved in repairing damaged DNA in cells. It can be useful against side effects from chemotherapy by repairing damaged tumor cells, which helps tumors to continue growing.[…]

Read More »

Marine Bacteria Could Potentially Detoxify Asbestos

There may be a new way to detoxify asbestos. Researchers at the University of Pennsylvania’s Department of Earth and Environmental Science are using bacteria from extreme marine environments. They are using a technique called bioremediation, which is a form of biotechnology that uses living organisms to remove toxins or contaminants[…]

Read More »

CRS-HIPEC for the Treatment of Peritoneal Mesothelioma

Researchers are studying the effectiveness of a multimodal treatment for peritoneal mesothelioma. The therapy involves cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, or CRS-HIPEC. Peritoneal mesothelioma is cancer of the abdominal lining. It is caused by inhaled or ingested asbestos fibers that travel to the lining of the abdomen. Over time,[…]

Read More »

Galinpepimut-S and Nivolumab are Effective and Safe for Mesothelioma

The combination of galinpepimut-S and nivolumab is showing promising results for mesothelioma. The study looked at patients who were refractory or relapsed after at least one standard treatment. The combination met safety and efficacy standards for treatment, leading to a completed phase one trial. The median overall survival, which was[…]

Read More »

Why Patients Quit PIPAC for Mesothelioma

PIPAC, or pressurized intraperitoneal aerosol chemotherapy, is showing promising results for mesothelioma, but patients don’t finish all their sessions. This is a problem because the patients then limit the effectiveness of their treatment. Researchers in France decided to figure out why patients are quitting their treatments early. Mesothelioma is a[…]

Read More »

Increased Doses of Radiation Improve Survival in Mesothelioma Patients

Researchers are trying to find out if increasing the dose of radiation can improve survival in mesothelioma patients. Radiation is typically seen as a secondary treatment after the combination of chemotherapy, surgery, and immunotherapy. Some doctors do not believe it is a valid treatment for mesothelioma patients because it can[…]

Read More »

Researchers are Searching for Mesothelioma Biomarkers

Mesothelioma could soon be diagnosed by blood test. Researchers in China have found a new method to analyze blood samples of people with mesothelioma. The researchers used gas chromatography-mass spectrometry (GC-MS). The hope was that the researchers would find biomarkers in the blood of mesothelioma patients that could help with[…]

Read More »

Finding Out How Asbestos Causes Mesothelioma

Finding Out How Asbestos Causes Mesothelioma Researchers are finding out why it takes a long time for mesothelioma to develop. A study in the Journal of Environmental Research found that the immune system sensing and interacting with particles changes how mesothelioma develops in the body. Researchers found that the main[…]

Read More »

Researchers Tried to Determine Which Second Line Treatment is Best for Mesothelioma

Researchers from China tried to determine whether immunotherapy or chemotherapy is better as a second line treatment option for relapsed pleural mesothelioma. There is no current standard therapy for people whose mesothelioma comes back, which makes it hard for doctors to make treatment decisions for patients. Mesothelioma is very aggressive,[…]

Read More »

YAP/TEAD Inhibitor is Showing Promising Results for Mesothelioma and NF2-Mutant Cancers

A YAP/TEAD inhibitor is showing promising results for people with mesothelioma and other cancers. The inhibitor, known as VT3989, was well tolerated and had good anti-tumor effects in cancer patients with mesothelioma and NF2 mutations. Results were recently published from the first human study. Seven of 69 patients had radiological[…]

Read More »

Skip to content